Synthetic Biologics Reports Second Quarter 2013 Financial Results and Operational Update
— Progress Cited On Three Infectious Disease Programs, Including Two Programs in Collaboration with Intrexon Corporation; C. difficile Prophylactic is Lead Anti-Infective Candidate — ROCKVILLE, Md., Aug. 14, 2013 /PRNewswire/ — Synthetic Biologics, Inc. (NYSE MKT: SYN), a developer of biologics focused on the prevention and treatment of serious infectious diseases, today reported financial results for […]
Synthetic Biologics Reports Second Quarter 2013 Financial Results and Operational Update Read More »